Peptic Ulcer Drugs Market Share: Leading Companies and Developments

The global peptic ulcer drugs market is witnessing significant growth, fueled by the increasing prevalence of peptic ulcers attributed to Helicobacter pylori (H. pylori) infections and the prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs). This surge in demand for peptic ulcer medications is driven by several factors, including evolving lifestyles, a growing geriatric population, and a preference for pharmaceutical treatments over surgery.

Discovering the Culprit: Nobel Laureates Barry Marshall and J. Robin Warren

In 2005, Drs. Barry Marshall and J. Robin Warren were awarded the Nobel Prize in Medicine for their groundbreaking discovery of H. pylori as a bacterial cause of peptic ulcer disease. This discovery revolutionized the understanding and treatment of peptic ulcers.

Key Drivers of the Peptic Ulcer Drugs Market

Several factors contribute to the growth of the peptic ulcer drugs market:

  1. H. pylori Infections: H. pylori infections remain a leading cause of peptic ulcers. The first-line treatment for these infections typically involves antibiotics and proton pump inhibitors.
  2. NSAID Use: The widespread use of NSAIDs, including aspirin and ibuprofen, is another significant contributor to peptic ulcers, especially among those who use them long-term.
  3. Lifestyle Factors: Unhealthy lifestyles, stress, and changing dietary habits have led to an increase in peptic ulcer cases.
  4. Geriatric Population: The rising geriatric population, as projected by the UN Database on World Population Ageing 2020, will further drive the prevalence of peptic ulcers.
  5. Awareness and Treatment: Greater awareness of treatment options, such as pharmaceuticals, has led to a preference for non-surgical interventions.

North America Takes the Lead

North America is at the forefront of the global peptic ulcer drugs market. With over 4 million Americans suffering from peptic ulcers each year, the regions mature healthcare market and research efforts have played a pivotal role in driving growth. The increased usage of NSAIDs and awareness of treatment options are expected to further boost the North American market.

Antibiotics Dominate the Market

In the forecast period, antibiotics are expected to dominate the global peptic ulcer drugs market. The triple therapy approach, which combines antibiotics and proton pump inhibitors, is the primary treatment for H. pylori infections. Increasing antibiotic resistance has led to a shift towards innovative treatments for bacterial infections, further strengthening the antibiotics segment.

Prominent Players in the Market

Key players in the peptic ulcer drugs market include Pfizer Inc., Abbvie Inc., GlaxoSmithKline plc., AstraZeneca plc, Boehringer Ingelheim GmbH, Daewoong Pharmaceutical Co., Ltd., Cadila Healthcare Ltd., Takeda Pharmaceutical, Eisai Co. Ltd., and Yuhan Corporation. These companies continue to introduce new products and collaborate on research and development efforts to meet the growing demand for peptic ulcer treatments.

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Our Blogs:

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of

services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.


Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746


Email: [email protected]

LinkedIn | Twitter

This press release first seen on Brilad

comtex tracking